OXB 202

Drug Profile

OXB 202

Alternative Names: EncorStat; OXB-202

Latest Information Update: 03 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Keratoplasty rejection

Most Recent Events

  • 23 Aug 2018 OXB 202 is available for licensing as of 23 Aug 2018. http://www.oxfordbiomedica.co.uk/pipeline
  • 23 Aug 2018 Oxford BioMedica plans a phase I/II trial for Keratoplasty rejection in the United Kingdom (Oxford BioMedica pipeline, August 2018)
  • 04 Dec 2017 corneal graft rejection gene therapy is still in preclinical development for keratoplasty rejection in the United Kingdom (Oxford BioMedica pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top